Autopsy report · NCT01532154
Fampridine Pregnancy Exposure Registry
Cause of deathSlow enrollment, also regulatory or ethics
“Due to low enrollment, registration closed in agreement with the Regulatory Agency”
Life of this trial
- Registered 3 years 8 months before it started.
- Ran for about 6 months before it stopped.
- 1 participant enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- Biogen
- Sponsor type
- Industry
- Conditions
- Multiple Sclerosis; Pregnancy
- Interventions
- Fampridine
- Participants
- 1
- Sites
- 1
- Countries
- France
Trials that died the same way
- PermeaDerm® vs. Mepilex-Ag® in Promoting Healing of Partial-thickness Burn Wounds
“Administratively closed prior enrollment of participants.” - A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
“Study closed to enrollment due to low accrual.” - Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
“Closed by sponsor, lack of enrollment.” - Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
“closed to enrollment due to slow patient accrual” - Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
“Closed to accrual to allow enrollment on another more promising trial.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.